CURRENT POSSIBILITIES OF DRUG THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER

CURRENT POSSIBILITIES OF DRUG THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER

Show other versions (1)

The advent of a variety of new drugs to treat castration-resistant prostate cancer (CRPC), which have demonstrated their efficacy in increasing overall and progression-free survival, has considerably enhanced treatment possibilities in this category of patients. The standard treatment of metastatic...

Full description

Bibliographic Details
Main Author:	A. S. Markova
Format:	Article
Language:	Russian
Published:	ABV-press 2014-07-01
Series:	Onkourologiâ
Subjects:	castration-resistant prostate cancer docetaxel cabazitaxel abiraterone acetate
Online Access:	https://oncourology.abvpress.ru/oncur/article/view/101

Similar Items

CURRENT POSSIBILITIES OF DRUG THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER
by: A. S. Markova
Published: (2014-07-01)

SEQUENTIAL THERAPY OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: NEW POSSIBILITIES
by: A. S. Markova, et al.
Published: (2018-10-01)

New developments in the treatment of castration resistant prostate cancer
by: Roxanne Wadia, et al.
Published: (2014-08-01)

Treatment sequencing in metastatic castrate-resistant prostate cancer
by: Oliver Sartor, et al.
Published: (2014-06-01)

The National Registry of treatment regimens in patients with metastatic castration-resistant prostate cancer in the Russian Federation
by: O. B. Karyakin, et al.
Published: (2019-10-01)

A changing landscape in castration resistant prostate cancer treatment
by: Alessandra eFelici, et al.
Published: (2012-07-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

THE POSSIBILITIES AND MECHANISMS OF ACTION OF HORMONE THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

THE POSSIBILITIES AND MECHANISMS OF ACTION OF HORMONE THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer
by: Qingzhong Hu, et al.
Published: (2013-07-01)

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)
by: Javier Puente, et al.
Published: (2019-08-01)

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance
by: Peng-Fei Zhang, et al.
Published: (2021-01-01)

Chemotherapy in the treatment of metastatic prostate cancer: the present state of the problem
by: B. Ya. Alekseev
Published: (2015-09-01)

The efficacy of abiraterone acetate in treating Taiwanese chemo-refractory metastatic castration-resistant prostate cancer patients
by: Tony Wu, et al.
Published: (2016-12-01)

Clinical experience with abiraterone acetate application in patients with castration-resistant prostate cancer
by: Ya V Gridneva, et al.
Published: (2014-09-01)

A COMPARISON OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS WITH THE USE OF ABIRATERONE ACETATE AND DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
by: A. V. Kondrashina, et al.
Published: (2018-05-01)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)

Cabazitaxel in the treatment of castration-resistant cancer: hitting the balance of efficacy and safety
by: M. I. Volkova, et al.
Published: (2019-06-01)

Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy
by: A. V. Rudakova, et al.
Published: (2014-11-01)

Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy
by: A. V. Rudakova, et al.
Published: (2014-11-01)

Prospects of 2nd line chemotherapy personalization in patients with metastatic castration-resistant prostate cancer
by: B. Ya. Alekseev, et al.
Published: (2016-12-01)

CURRENT POSSIBILITIES OF TREATMENT FOR VISCERAL METASTASES IN PATIENTS WITH METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. V. Govorov, et al.
Published: (2014-07-01)

CURRENT POSSIBILITIES OF TREATMENT FOR VISCERAL METASTASES IN PATIENTS WITH METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. V. Govorov, et al.
Published: (2014-07-01)

Predictors of overall survival in patients with metastatic castration-resistant prostate cancer
by: A. S. Markova, et al.
Published: (2015-06-01)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
by: Jian-Ri Li, et al.
Published: (2017-11-01)

Efficacy and safety of enzalutamide, abiraterone and cabazitaxel in post-docetaxel treatment of castration-resistant prostate cancer: meta-analysis data
by: P. V. Mazin, et al.
Published: (2018-01-01)

Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
by: Natalia Jiménez, et al.
Published: (2020-11-01)

Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
by: El-Amm J, et al.
Published: (2017-07-01)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
by: Yoshinori Yanai, et al.
Published: (2019-07-01)

A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer
by: Takehiko Nakasato, et al.
Published: (2020-03-01)

Retreatment with cabazitaxel in a long-surviving patient with castration-resistant prostate cancer and visceral metastasis
by: Raquel Luque Caro, et al.
Published: (2018-01-01)

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
by: Takashi Nagai, et al.
Published: (2018-03-01)

Real-world experience with abiraterone in metastatic castration-resistant prostate cancer
by: Yasar Ahmed, et al.
Published: (2017-01-01)

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
by: Patel SA, et al.
Published: (2017-08-01)

A Study on the Clinical Outcome of Abiraterone Acetate in Castration Resistant Prostate Cancer Patients
by: Aloysius James, et al.
Published: (2018-01-01)

Second line chemotherapy in patients with castration-refractory prostate cancer. Ftom clinical studies to practice
by: B. Ya. Alekseev, et al.
Published: (2019-04-01)

EVALUATION OF EFFECT OF PROLONGED ACTION SOMATOSTATIN ANALOGUE – OCREOTIDE-DEPO – ON THE FOLLOWING HORMONAL AND CYTOTOXIC THERAPY IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (М-CRPC)
by: S. V. Mishugin, et al.
Published: (2017-11-01)

External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer
by: Yun-Jie Yang, et al.
Published: (2018-01-01)

Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
by: Donald Colbourn
Published: (2012-06-01)

Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study
by: Takashi Matsumoto, et al.
Published: (2021-06-01)